Received Mar 24, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | UNK | — |
it would be great if we could see a color change. With it appearing just like our Hep A, there's a significant increase in likelihood of errors being made; it would be great if we could see a color change. With it appearing just like our Hep A, there's a significant increase in likelihood of errors being made; This non-serious case was reported by a nurse and described the occurrence of circumstance or information capable of leading to medication error in a patient who received Herpes zoster (Shingrix) for prophylaxis. On an unknown date, the patient received Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced circumstance or information capable of leading to medication error (Verbatim: it would be great if we could see a color change. With it appearing just like our Hep A, there's a significant increase in likelihood of errors being made) and product color issue (Verbatim: it would be great if we could see a color change. With it appearing just like our Hep A, there's a significant increase in likelihood of errors being made). The outcome of the circumstance or information capable of leading to medication error and product color issue were not applicable. Additional Information: GSK Receipt Date: 16-MAR-2026 The reporter had concerned about the new Shingrix vaccine. While it was great to see improved convenience, it would be great if they could see a color change. With it appearing just like the Hep A, there was a significant increase in likelihood of errors being made. Please let know how that can be addressed. The batch number was not provided and a request for this information has been made.